Cadrenal Therapeutics, Inc. (CVKD)
CVKD moved a median of 0.00% 30 minutes after news, and -0.56% by the close. How CVKD actually reacts to news — the realized, point-in-time move the market made, measured across 264 labeled events over the last three years with zero look-ahead.
CVKD’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 37% | 257 |
| 30-min | 0.00% | 50% | 260 |
| 60-min | +0.05% | 52% | 264 |
| to close | -0.56% | 38% | 263 |
| Middle 50% of CVKD reactions | -1.87% to +2.32% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 264 |
Half of all Cadrenal Therapeutics, Inc. news events land between -1.87% and +2.32% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CVKD moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CVKD's baseline. Nothing else.
Recent CVKD events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form S-8 Cadrenal Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -3.79% | -6.56% | |
| Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics | Press release | GlobeNewswire | -6.50% | -3.73% | |
| Form 8-K Cadrenal Therapeutics, For: Oct 07 | SEC filing · Form 8-K | SEC EDGAR | -6.50% | -3.73% | |
| Form 8-K Cadrenal Therapeutics, For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.82% | |
| Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference | Press release | GlobeNewswire | +0.00% | +0.90% | |
| Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference | Press release | GlobeNewswire | +0.05% | -5.88% | |
| Form S-8 Cadrenal Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.79% | -3.17% | |
| Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia | Press release | GlobeNewswire | -5.49% | +6.71% | |
| Form 8-K Cadrenal Therapeutics, For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | -5.49% | +6.71% | |
| Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process | Press release | GlobeNewswire | +0.00% | -0.53% | |
| Form 10-Q Cadrenal Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -0.53% | |
| Form 8-K Cadrenal Therapeutics, For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.53% | |
| Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation | Press release | GlobeNewswire | +0.51% | -0.51% | |
| Form ARS Cadrenal Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +3.57% | |
| Form DEF 14A Cadrenal Therapeutics, For: Sep 24 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +3.57% | |
| Form DEFA14A Cadrenal Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +3.57% | |
| Form PRE 14A Cadrenal Therapeutics, For: Jul 23 | SEC filing · Form PRE | SEC EDGAR | -0.49% | -0.49% | |
| Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation | Press release | GlobeNewswire | -0.47% | +1.40% | |
| Form 8-K Cadrenal Therapeutics, For: Jul 21 | SEC filing · Form 8-K | SEC EDGAR | -0.47% | +1.40% | |
| Form EFFECT Cadrenal Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -0.47% | +1.40% | |
| Form 8-K Cadrenal Therapeutics, For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | +2.73% | -5.00% | |
| Form D Cadrenal Therapeutics, | SEC filing · Form D | SEC EDGAR | +0.00% | -2.10% | |
| Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress | Press release | GlobeNewswire | -10.88% | -21.43% | |
| Form S-3 Cadrenal Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | -1.25% | +0.41% | |
| Form 8-K Cadrenal Therapeutics, For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | -10.88% | -21.43% | |
| Form 8-K Cadrenal Therapeutics, For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +1.94% | +16.50% | |
| Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | -1.72% | -0.94% | |
| Form 8-K Cadrenal Therapeutics, For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +1.01% | +12.46% | |
| Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress | Press release | GlobeNewswire | +0.00% | -2.93% | |
| Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease | Press release | GlobeNewswire | +2.06% | +7.36% | |
| Form 8-K Cadrenal Therapeutics, For: Jun 18 | SEC filing · Form 8-K | SEC EDGAR | +2.06% | +7.36% | |
| Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 | Press release | GlobeNewswire | +1.84% | -12.37% | |
| Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event | Press release | GlobeNewswire | +0.00% | -3.68% | |
| Form 8-K Cadrenal Therapeutics, For: May 28 | SEC filing · Form 8-K | SEC EDGAR | +6.21% | +2.86% | |
| Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 | Press release | GlobeNewswire | +0.00% | +3.82% | |
| Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA | Press release | GlobeNewswire | +1.53% | -2.75% | |
| Form 10-Q Cadrenal Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.53% | -2.75% | |
| Form 8-K Cadrenal Therapeutics, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | +1.53% | -2.75% | |
| Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT) | Press release | GlobeNewswire | +0.00% | +21.94% | |
| Form 8-K Cadrenal Therapeutics, For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +21.94% | |
| Form EFFECT Cadrenal Therapeutics, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +21.94% | |
| Form S-3 Cadrenal Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +1.82% | +3.26% | |
| Form D Cadrenal Therapeutics, | SEC filing · Form D | SEC EDGAR | +0.00% | -4.00% | |
| Form 8-K Cadrenal Therapeutics, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.67% | |
| Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting | Press release | GlobeNewswire | +3.00% | +18.25% | |
| Form 10-K Cadrenal Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +3.00% | +18.25% | |
| Form 8-K Cadrenal Therapeutics, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | +3.00% | +18.25% | |
| Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes | Press release | GlobeNewswire | +1.69% | -6.75% | |
| Form 8-K Cadrenal Therapeutics, For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +1.69% | -6.75% | |
| Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion | Press release | GlobeNewswire | -1.15% | -1.49% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CVKD section they belong to.
Where else CVKD is measured.
CVKD earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cadrenal Therapeutics, Inc.'s median reaction calculated?
Every labeled CVKD news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 264 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of CVKD's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CVKD's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.